Table 3.
Effectiveness Thresholds | |||||
---|---|---|---|---|---|
$50,000/QALY % | $100,000/QALY % | $150,000/QALY % | $200,000/QALY % | $250,000/QALY % | |
Versus cDMARD | |||||
Sarilumab | 0 | 0 | 1 | 26 | 68 |
Adalimumab | 0 | 0 | 0 | 2 | 20 |
Versus Adalimumab | |||||
Sarilumab | 100 | 100 | 100 | 100 | 100 |
cDMARD = conventional disease-modifying antirheumatic drug; QALY = quality-adjusted life-years.